Counterpoint: Should Thoracoscopic Talc Pleurodesis Be the First Choice Management for Malignant Pleural Effusion? No

Chest

Volumn 142, Issue 1, 2012, Pages 17-19

  Light, Richard W ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TALC;

HUMAN; METHODOLOGY; NOTE; PLEURA EFFUSION; PLEURODESIS; THORACOSCOPY;

HUMANS; PLEURAL EFFUSION, MALIGNANT; PLEURODESIS; TALC; THORACOSCOPY;

MLCS; MLOWN;

EID: 84863792905     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-1087     Document Type: Editorial

References (14)

1. Light, RW, Pleural Diseases, 5th ed., 2007, Lippincott, Williams and Wilkins, Baltimore, MD.
2. Tremblay, A, Robbins, S, Berthiaume, L, Michaud, G, Natural history of asymptomatic pleural effusions in lung cancer patients. J Bronchol 14:14 (2007), 98–100.
3. Putnam, JB Jr, Light, RW, Rodriguez, RM, et al. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer 86:10 (1999), 1992–1999.
4. Tremblay, A, Michaud, G, Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest 129:2 (2006), 362–368.
5. x) catheter. Ann Thorac Surg 85:3 (2008), 1049–1055.
6. Van Meter, ME, McKee, KY, Kohlwes, RJ, Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions: a systematic review. J Gen Intern Med 26:1 (2011), 70–76.
7. Fysh ETH, Waterer GW, Kendall P, et al. Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion [published online ahead of print March 8, 2012]. Chest doi:10.1378/chest.11-2657.
8. Dresler, CM, Olak, J, Herndon, JE II, et al., Cooperative Groups Cancer and Leukemia Group B, Eastern Cooperative Oncology Group, North Central Cooperative Oncology Group, Radiation Therapy Oncology Group, Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 127:3 (2005), 909–915.
9. Yim, AP, Chan, AT, Lee, TW, Wan, IY, Ho, JK, Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion. Ann Thorac Surg 62:6 (1996), 1655–1658.
10. Lee, YC, Baumann, MH, Maskell, NA, et al. Pleurodesis practice for malignant pleural effusions in five English-speaking countries: survey of pulmonologists. Chest 124:6 (2003), 2229–2238.
11. da Paschoalini, MS, Vargas, FS, Marchi, E, et al. Prospective randomized trial of silver nitrate vs talc slurry in pleurodesis for symptomatic malignant pleural effusions. Chest 128:2 (2005), 684–689.
12. Neto, JD, de Oliveira, SF, Vianna, SP, Terra, RM, Efficacy and safety of iodopovidone pleurodesis in malignant pleural effusions. Respirology 15:1 (2010), 115–118.
13. Maskell, NA, Lee, YC, Gleeson, FV, Hedley, EL, Pengelly, G, Davies, RJ, Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med 170:4 (2004), 377–382.
14. Janssen, JP, Collier, G, Astoul, P, et al. Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet 369:9572 (2007), 1535–1539.